Revenue: As of FY2026 Q2, the actual value is USD 3.9 M.EPS: As of FY2026 Q2, the actual value is USD -0.03.<h3>Financial Highlights for Q2-FY26</h3><ul><li>Revenue: Increased 19% to $3.9 million from $3.3 million in the corresponding prior year period.</li><li>Gross Margin: 81.9% for the three months ended June 30, 2025, compared to 75.3% in the corresponding prior year quarter.</li><li>Net Loss: Decreased to $0.77 million, or $0.03 per share, from a net loss of $1.7 million, or $0.07 per share, a 53.3% improvement from the corresponding prior year quarter.</li></ul><h3>Operational Highlights for Q2-FY26</h3><ul><li>Recurring (TaaS) Technology Fees: Rose 4.2% from the corresponding prior year period, to $3.5 million, representing 88.7% of total revenue for Q2-FY26.</li><li>Customer Retention: The company sustained strong customer retention driven by high-quality, cardiologist- and patient-friendly services.</li><li>Regulatory Approval: Progress in securing regulatory approval across key international markets, including Canada, Saudi Arabia, and Argentina.</li><li>U.S. Market Expansion: Continued expansion with penetration across thousands of cardiologists in hundreds of centers, through direct sales force efforts and strategic alliances with three of the top GPOs representing 90% of U.S. hospitals.</li></ul><h3>Outlook / Guidance</h3>Biotricity is extending its reach into international markets to increase accessibility and strengthen its global footprint. The company is also diversifying its portfolio by entering adjacent fields such as sleep and pulmonology, reinforcing its position as a leader in connected healthcare.

Biotricity | 8-K: FY2026 Q2 Revenue: USD 3.9 M